Cargando…

Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)

BACKGROUND: Obesity is associated with poorly differentiated and advanced prostate cancer and increased mortality. In preclinical models, caloric restriction delays prostate cancer progression and prolongs survival. We sought to determine if weight loss (WL) in men with prostate cancer prior to radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Henning, Susanne M, Galet, Colette, Gollapudi, Kiran, Byrd, Joshua B., Liang, Pei, Li, Zhaoping, Grogan, Tristan, Elashoff, David, Magyar, Clara E., Said, Jonathan, Cohen, Pinchas, Aronson, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986584/
https://www.ncbi.nlm.nih.gov/pubmed/29203893
http://dx.doi.org/10.1038/s41391-017-0001-1
_version_ 1783328952090099712
author Henning, Susanne M
Galet, Colette
Gollapudi, Kiran
Byrd, Joshua B.
Liang, Pei
Li, Zhaoping
Grogan, Tristan
Elashoff, David
Magyar, Clara E.
Said, Jonathan
Cohen, Pinchas
Aronson, William J.
author_facet Henning, Susanne M
Galet, Colette
Gollapudi, Kiran
Byrd, Joshua B.
Liang, Pei
Li, Zhaoping
Grogan, Tristan
Elashoff, David
Magyar, Clara E.
Said, Jonathan
Cohen, Pinchas
Aronson, William J.
author_sort Henning, Susanne M
collection PubMed
description BACKGROUND: Obesity is associated with poorly differentiated and advanced prostate cancer and increased mortality. In preclinical models, caloric restriction delays prostate cancer progression and prolongs survival. We sought to determine if weight loss (WL) in men with prostate cancer prior to radical prostatectomy affects tumor apoptosis and proliferation, and if WL effects other metabolic biomarkers. METHODS: In this Phase II prospective trial, overweight and obese men scheduled for radical prostatectomy were randomized to a 5–8 week WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity or to a control group. The primary endpoint was apoptotic index in the radical prostatectomy malignant epithelium. Secondary endpoints were proliferation (Ki67) in the radical prostatectomy tissue, body weight, body mass index (BMI), waist to hip ratio, body composition, and serum PSA, insulin, triglyceride, cholesterol, testosterone, estradiol, leptin, adiponectin, interleukin 6, interleukin 8, insulin-like growth factor 1, and IGF binding protein 1. RESULTS: Twenty-three patients were randomized to the WL intervention and twenty-one patients to the control group. Subjects in the intervention group had significantly more weight loss (WL:−3.7 ± 0.5 kg; Control:−1.6 ± 0.5 kg; p=0.007) than the control group and total fat mass was significantly reduced (WL:−2.1 ± 0.4; Control: 0.1 ± 0.3; p=0.015). There was no significant difference in apoptotic or proliferation index between the groups. Among the other biomarkers, triglyceride and insulin levels were significantly decreased in the WL compared to the control group. CONCLUSIONS: In summary, this short-term WL program prior to radical prostatectomy resulted in significantly more WL in the intervention vs. the control group and was accompanied by significant reductions in body fat mass, circulating triglycerides, and insulin. However, no significant changes were observed in malignant epithelium apoptosis or proliferation. Future studies should consider a longer term or more intensive weight loss intervention.
format Online
Article
Text
id pubmed-5986584
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-59865842018-06-05 Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128) Henning, Susanne M Galet, Colette Gollapudi, Kiran Byrd, Joshua B. Liang, Pei Li, Zhaoping Grogan, Tristan Elashoff, David Magyar, Clara E. Said, Jonathan Cohen, Pinchas Aronson, William J. Prostate Cancer Prostatic Dis Article BACKGROUND: Obesity is associated with poorly differentiated and advanced prostate cancer and increased mortality. In preclinical models, caloric restriction delays prostate cancer progression and prolongs survival. We sought to determine if weight loss (WL) in men with prostate cancer prior to radical prostatectomy affects tumor apoptosis and proliferation, and if WL effects other metabolic biomarkers. METHODS: In this Phase II prospective trial, overweight and obese men scheduled for radical prostatectomy were randomized to a 5–8 week WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity or to a control group. The primary endpoint was apoptotic index in the radical prostatectomy malignant epithelium. Secondary endpoints were proliferation (Ki67) in the radical prostatectomy tissue, body weight, body mass index (BMI), waist to hip ratio, body composition, and serum PSA, insulin, triglyceride, cholesterol, testosterone, estradiol, leptin, adiponectin, interleukin 6, interleukin 8, insulin-like growth factor 1, and IGF binding protein 1. RESULTS: Twenty-three patients were randomized to the WL intervention and twenty-one patients to the control group. Subjects in the intervention group had significantly more weight loss (WL:−3.7 ± 0.5 kg; Control:−1.6 ± 0.5 kg; p=0.007) than the control group and total fat mass was significantly reduced (WL:−2.1 ± 0.4; Control: 0.1 ± 0.3; p=0.015). There was no significant difference in apoptotic or proliferation index between the groups. Among the other biomarkers, triglyceride and insulin levels were significantly decreased in the WL compared to the control group. CONCLUSIONS: In summary, this short-term WL program prior to radical prostatectomy resulted in significantly more WL in the intervention vs. the control group and was accompanied by significant reductions in body fat mass, circulating triglycerides, and insulin. However, no significant changes were observed in malignant epithelium apoptosis or proliferation. Future studies should consider a longer term or more intensive weight loss intervention. 2017-12-04 2018-06 /pmc/articles/PMC5986584/ /pubmed/29203893 http://dx.doi.org/10.1038/s41391-017-0001-1 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Henning, Susanne M
Galet, Colette
Gollapudi, Kiran
Byrd, Joshua B.
Liang, Pei
Li, Zhaoping
Grogan, Tristan
Elashoff, David
Magyar, Clara E.
Said, Jonathan
Cohen, Pinchas
Aronson, William J.
Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title_full Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title_fullStr Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title_full_unstemmed Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title_short Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128)
title_sort phase ii prospective randomized trial of weight loss prior to radical prostatectomy (pcan-17-0128)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986584/
https://www.ncbi.nlm.nih.gov/pubmed/29203893
http://dx.doi.org/10.1038/s41391-017-0001-1
work_keys_str_mv AT henningsusannem phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT galetcolette phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT gollapudikiran phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT byrdjoshuab phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT liangpei phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT lizhaoping phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT grogantristan phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT elashoffdavid phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT magyarclarae phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT saidjonathan phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT cohenpinchas phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128
AT aronsonwilliamj phaseiiprospectiverandomizedtrialofweightlosspriortoradicalprostatectomypcan170128